

Australian Medicines Terminology v3 Model v20141231

Release Note

31 December 2014

Approved for external use

Summary

EP-1960:2014 Australian Medicines Terminology v3 Model v20141231

The Australian Medicines Terminology (AMT) is updated, verified and validated, and released monthly to incorporate new content, enhance existing content, and make more effective use of the terminology. Routine updating continuously improves and extends the AMT's coverage of medicines used in the Australian health sector.

Release rationale

This release of the AMT includes products that become available on the Schedule of Pharmaceutical Benefits including the Repatriation Pharmaceutical Benefits Schedule (RPBS) on or before 1 January 2015.

Migration assistance

The National Clinical Terminology and Information Service (NCTIS) has developed a series of "delta" files that detail the differences between the last AMT v2 release (v2.56, May 2014) and the first AMT v3 Production release (June 2014). These files can help AMT v2 implementers to migrate to AMT v3.

These delta files include removed AMT v2 concepts/descriptions, newly added AMT v3 concepts/descriptions, and changed AMT v2 descriptions (where the conceptid stays the same but the description text has changed in AMT v3). These files can be used to determine which AMT v2 components that exist in a current implementation have changed in some way in AMT v3, and will therefore need to be migrated.

Any licence holder interested in obtaining these delta files should make a request via the NEHTA Help Desk using help@nehta.gov.au.

Identifying the version of this release of AMT

When using codes from this release (for example, in clinical documents, maps, or terminology servers) the following string should be used to identify the version of this release:

```
http://snomed.info/sct/900062011000036108/version/20141231
```

For example, in an HL7 CDA document, the version of this release may be encoded in a Concept Descriptor field named *xyz* using the *codeSystemVersion* attribute as follows:

```
<xyz code="33256011000036105"  
  codeSystem="2.16.840.1.113883.6.96"  
  codeSystemName="Australian Medicines Terminology (AMT)"  
  codeSystemVersion="http://snomed.info/sct/900062011000036108/version/20141231"  
  displayName="Lorano 10 mg tablet: uncoated, 30"/>
```

Package inclusions

New

None

Updated

Identifier	Name and version
NEHTA-1959:2014	<i>Australian Medicines Terminology v3 Model – Release Note v20141231</i> (this document)
NEHTA-1958:2014	<i>Australian Medicines Terminology – Data v20141231</i>

Audience

The audience for this end product is any licence holder with a practical interest in using the AMT data files including: software developers, content/mapping developers, testers, information system suppliers, analysts, terminology/classification specialists, health IT professionals and researchers.

Capabilities

All major changes between the AMT v2 and v3 data model and distribution formats are outlined in the *Australian Medicines Terminology v2 to v3 Migration Guide v2.0*, which is available from <https://www.nehta.gov.au/implementation-resources/ehealth-foundations/australian-medicines-terminology-v3-common>.

AMT v3 viewers

The AMT terminology viewers for Windows and Mac operating systems currently used for AMT v2 will not be able to browse the AMT v3 data.

Users can search the AMT content and browse the AMT hierarchies via the Minnow application¹, which is available as a free download. Further information including features, system requirements, installation instructions, help manual and access to the download is available at <http://aehrc.com/minnow>.

Data file bundle

The data file (Australian Medicines Terminology – Data v20141231) is in ZIP file format. The contents are listed below.

The data in this file is in “Release Format 2” (RF2) format², which aligns to the SNOMED CT³ and SNOMED CT-AU bundle structure, and makes available a number of different release types, namely “Full”, “Snapshot” and “Delta”.

- ❖ AMT_Release_AU1000168_20141231
 - RF2Release
 - Full

¹ Minnow was developed by the Australian e-Health Research Centre (AEHRC).

² For information about RF2, see the *SNOMED CT Technical Implementation Guide*, which is available at: http://ihtsdo.org/fileadmin/user_upload/doc/.

³ This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO®). All rights reserved. SNOMED CT was originally created by The College of American Pathologists. IHTSDO®, SNOMED® and SNOMED CT® are registered trademarks of the IHTSDO.

- Refset
 - Content
 - der2_ccsRefset_StrengthFull_AU1000168_20141231.txt
 - der2_Refset_ContainerizedTradeProductPackFull_AU1000168_20141231.txt
 - der2_Refset_TradeProductPackFull_AU1000168_20141231.txt
 - der2_ccsRefset_UnitOfUseQuantityFull_AU1000168_20141231.txt
 - der2_Refset_MedicinalProductPackFull_AU1000168_20141231.txt
 - der2_Refset_TradeProductFull_AU1000168_20141231.txt
 - der2_ccsRefset_UnitOfUseSizeFull_AU1000168_20141231.txt
 - der2_Refset_MedicinalProductFull_AU1000168_20141231.txt
 - der2_Refset_TradeProductUnitOfUseFull_AU1000168_20141231.txt
 - der2_cciRefset_SubpackQuantityFull_AU1000168_20141231.txt
 - der2_Refset_MedicinalProductUnitOfUseFull_AU1000168_20141231.txt
 - der2_cRefset_AssociationReferenceFull_AU1000168_20141231.txt
 - der2_cRefset_AttributeValueFull_AU1000168_20141231.txt
 - Map
 - der2_csRefset_SubstanceToSnomedCtauMappingFull_AU1000168_20141231.txt
 - der2_iRefset_ArtgIdFull_AU1000168_20141231.txt
 - Language
 - der2_cRefset_LanguageFull-en-AU_AU1000168_20141231.txt
 - Metadata
 - der2_cciRefset_RefsetDescriptorFull_AU1000168_20141231.txt
 - der2_ciRefset_DescriptionTypeFull_AU1000168_20141231.txt
 - der2_ssRefset_ModuleDependencyFull_AU1000168_20141231.txt
- Terminology
 - sct2_Concept_Full_AU1000168_20141231.txt
 - sct2_Description_Full-en-AU_AU1000168_20141231.txt
 - sct2_Identifier_Full_AU1000168_20141231.txt
 - sct2_Relationship_Full_AU1000168_20141231.txt
- Snapshot
 - Refset
 - Content
 - der2_ccsRefset_StrengthSnapshot_AU1000168_20141231.txt
 - der2_Refset_ContainerizedTradeProductPackSnapshot_AU1000168_20141231.txt
 - der2_Refset_TradeProductPackSnapshot_AU1000168_20141231.txt
 - der2_ccsRefset_UnitOfUseQuantitySnapshot_AU1000168_20141231.txt
 - der2_Refset_MedicinalProductPackSnapshot_AU1000168_20141231.txt
 - der2_Refset_TradeProductSnapshot_AU1000168_20141231.txt
 - der2_ccsRefset_UnitOfUseSizeSnapshot_AU1000168_20141231.txt
 - der2_Refset_MedicinalProductSnapshot_AU1000168_20141231.txt
 - der2_Refset_TradeProductUnitOfUseSnapshot_AU1000168_20141231.txt
 - der2_cciRefset_SubpackQuantitySnapshot_AU1000168_20141231.txt
 - der2_Refset_MedicinalProductUnitOfUseSnapshot_AU1000168_20141231.txt

- der2_cRefset_AssociationReferenceSnapshot_AU1000168_20141231.txt
- der2_cRefset_AttributeValueSnapshot_AU1000168_20141231.txt
- Map
 - der2_csRefset_SubstanceToSnomedCtauMappingSnapshot_AU1000168_20141231.txt
 - der2_iRefset_ArtgIdSnapshot_AU1000168_20141231.txt
- Language
 - der2_cRefset_LanguageSnapshot-en-AU_AU1000168_20141231.txt
- Metadata
 - der2_cciRefset_RefsetDescriptorSnapshot_AU1000168_20141231.txt
 - der2_ciRefset_DescriptionTypeSnapshot_AU1000168_20141231.txt
 - der2_ssRefset_ModuleDependencySnapshot_AU1000168_20141231.txt
- Terminology
 - sct2_Concept_Snapshot_AU1000168_20141231.txt
 - sct2_Description_Snapshot-en-AU_AU1000168_20141231.txt
 - sct2_Identifier_Snapshot_AU1000168_20141231.txt
 - sct2_Relationship_Snapshot_AU1000168_20141231.txt
- Delta
 - Refset
 - Content
 - der2_ccsRefset_StrengthDelta_AU1000168_20141231.txt
 - der2_Refset_ContainerizedTradeProductPackDelta_AU1000168_20141231.txt
 - der2_Refset_TradeProductPackDelta_AU1000168_20141231.txt
 - der2_ccsRefset_UnitOfUseQuantityDelta_AU1000168_20141231.txt
 - der2_Refset_MedicinalProductPackDelta_AU1000168_20141231.txt
 - der2_Refset_TradeProductDelta_AU1000168_20141231.txt
 - der2_ccsRefset_UnitOfUseSizeDelta_AU1000168_20141231.txt
 - der2_Refset_MedicinalProductDelta_AU1000168_20141231.txt
 - der2_Refset_TradeProductUnitOfUseDelta_AU1000168_20141231.txt
 - der2_cciRefset_SubpackQuantityDelta_AU1000168_20141231.txt
 - der2_Refset_MedicinalProductUnitOfUseDelta_AU1000168_20141231.txt
 - der2_cRefset_AssociationReferenceDelta_AU1000168_20141231.txt
 - der2_cRefset_AttributeValueDelta_AU1000168_20141231.txt
 - Map
 - der2_csRefset_SubstanceToSnomedCtauMappingDelta_AU1000168_20141231.txt
 - der2_iRefset_ArtgIdDelta_AU1000168_20141231.txt
 - Language
 - der2_cRefset_LanguageDelta-en-AU_AU1000168_20141231.txt
 - Metadata
 - der2_cciRefset_RefsetDescriptorDelta_AU1000168_20141231.txt
 - der2_ciRefset_DescriptionTypeDelta_AU1000168_20141231.txt
 - der2_ssRefset_ModuleDependencyDelta_AU1000168_20141231.txt
 - Terminology
 - sct2_Concept_Delta_AU1000168_20141231.txt

- sct2_Description_Delta-en-AU_AU1000168_20141231.txt
- sct2_Identifier_Delta_AU1000168_20141231.txt
- sct2_Relationship_Delta_AU1000168_20141231.txt

Updated content

New content

The *Attribute Value reference set* has been added in this release.

Significant issues

ID	Description
----	-------------

CQW-82	Due to an AMT v3 editorial rule change ⁴ , a number of Trade Product (TP) descriptions have been expanded to a fuller brand name incorporating the “suffix” from v2. The related v2 TP concepts have been retired in the v20140630 release to ensure that there are no historical data implications where the TP concept ID may be stored in a PCEHR. Users who have previously mapped to v2 TP concepts will need to review and update their existing maps.
--------	--

CQW-74	Due to an AMT v3 model change ⁵ , a number of Medicinal Product Unit of Use (MPUU) descriptions have been expanded to include the Unit of Use size. These new MPUUs include nutritional products and diluents where the descriptions in v2 did not include a Unit of Use size and as a result there was no differentiation at the MPUU level for the differing pack sizes. Users who have previously mapped to v2 MPUU concepts will need to review and update their existing maps.
--------	---

Note that this change also affects the Trade Product Unit of Use (TPUU) for these concepts. **Users who have previously mapped to v2 TPUU concepts will need to review and update their existing maps.**

CQW-96	Due to an AMT v3 editorial rule change ⁶ , subpack authoring has been expanded to include other product types as well as oral contraceptives. The result of this is the addition of new Medicinal Product Pack (MPP) and Containered Trade Product Pack (CTPP) concepts for the single pack where these did not exist in v2.
--------	---

Concept counts

The figures quoted here have been extracted from the notable concept reference sets and include both active and inactive concepts. See the *AMT v3 Development approach for reference sets*⁷ for information about these reference sets and the members of the reference sets.

Concept	Current count	Changes since the last release
Medicinal Product (MP)	1864	8
Medicinal Product Unit of Use (MPUU)	4892	23
Medicinal Product Pack (MPP)	8603	46
Trade Product (TP)	6820	28
Trade Product Unit of Use (TPUU)	11452	46

⁴ The *AMT v3 Model Editorial Rules* are available at: <http://www.nehta.gov.au/implementation-resources/ehealth-foundations/australian-medicines-terminology-common>.

⁵ See note 4.

⁶ See note 4.

⁷ Available at <http://www.nehta.gov.au/implementation-resources/ehealth-foundations/australian-medicines-terminology-common>.

Concept	Current count	Changes since the last release
Trade Product Pack (TPP)	16952	93
Containerised Trade Product Pack (CTPP)	17985	98
Total	68568	342

Known issues

NEHTA has identified the following open issue in this release.

Due to the re-modelling of the AMT v2 to AMT v3, there currently exist some instances of Medicinal Product Unit of Use (MPUU) concepts in the data where the FSN terms and/or modelling may be potentially interpreted as being ambiguous. These apply to instances where the Basis of Strength Substance (BoSS) is different to the Pharmaceutical Ingredient (PI). For example, "amoxicillin" is in the MPUU FSN (representing the BoSS) while "amoxicillin trihydrate" is the actual substance present (representing the PI; but is not included in the current AMT v3 model). The AMT v3 model will be examined to address this issue.

Editorial rule deviations

The following rules are in the process of implementation or have yet to be implemented. The identifiers provided below align with those in the *AMT v3 Model Editorial Rules*.⁸

Preferred Term descriptions

Currently, some AMT descriptions may differ slightly to those expected from the relevant editorial rules, due to the automated process used in authoring the terminology. In most cases additional information has been added to the descriptions beyond the stated editorial rules. AMT v3 implementers are advised to contact the NCTIS via help@nehta.gov.au if they have any concerns about this issue. Details of any existing deviations are documented here.

AMT-APP-STR-4	If the number of units is equal to or greater than 1000, the next higher unit level should be used (for example, 2 g should be used in preference to 2000 mg). This rule has yet to be fully implemented with large volume injections.
AMT-APP-STR-5	A space will be inserted between the strength value and strength unit of measure. This space must be a non-breaking space to ensure that the strength value and strength unit expressions are always kept together.
AMT-APP-STR-6	Strength units of measure will be expressed as singular if the value is less than or equal to unity, and will be expressed as plural if the value is greater than unity. This rule applies to full descriptions only – it does not apply to abbreviations.
AMT-APP-STR-10	Where the strength or volume of a product is not a set single value but may vary within a given range, the strength or volume will be expressed as the range, with the lower numerical value, followed by the word "to" and then the upper numerical and the relevant units.
AMT-APP-STR-11	Where the strength or volume of a product is expressed with a lower limit only (that is, contains not less than, contains equal to or greater than, more than) the strength or volume will be expressed with the word "minimum" followed by the relevant strength or volume.

⁸ See note 4.

AMT-MP-PT-4	For Medicinal Products with greater than three intended active ingredients, the AMT authors may create a clinically intuitive name based on the review of each individual product.
Appendix C.4 Waters of hydration	<p>Waters of hydration shall only be expressed for each ingredient in the Fully Specified Name where hydration is present and the modification is deemed to be clinically significant (according to Appendix B). Where an ingredient is found to be anhydrous or dried, this shall not be expressed.</p> <p>Note that waters of hydration shall only be expressed in the Preferred Term if they are part of the proprietary name.</p>
Appendix C.6 Medicinal Product PT sequence of ingredients	<p>Ingredients will be sequenced in alphabetical order within the FSN.</p> <p>For multi-ingredient products, the order of the ingredients in the PT will be based on the order used by the innovator product. All subsequent products with the same combination of ingredients will follow the order of the innovator product.</p> <p>Note that some ongoing anomalies exist in PT order and these will be rectified over time.</p>
Appendix D Examples of products with more than three ingredients	<p>This list is not exhaustive and is provided to illustrate examples of products where more than three ingredients will be specified as part of the Medicinal Product PT.</p> <p>This list currently contains specific examples, but may contain product groups (for example, vaccines and parenteral nutrition solutions).</p> <p>For reasons of clinical safety, any products containing paracetamol or pseudoephedrine as an active ingredient will always show this ingredient as one of the three listed ingredients.</p>
Appendix E.1 Strength expressions for continuous semisolid preparations such as creams, gels, ointments	If a product is applied locally and is intended to have a local effect then a single strength as % should be displayed. For example: aciclovir 5% cream. If a product is applied locally and is intended to have a systemic effect then a single strength as mg (or similar) should be displayed.
Appendix F.2 Preferred Terms	AMT Preferred Terms will not state the descriptor for units of measure where the measure is International unit, pressor unit or Kallikrein Inactivator units. These are expressed in the PT as "units". All other Preferred Term units of measure are represented with the same description as the Fully Specified Name.
Appendix K.1 Strength expressions for vaccines	Strength will be represented as part of the Fully Specified Name but will not be included in Preferred Terms for vaccines. Where two products exist with different amounts of antigen intended for different populations, a term describing the population, rather than strength, will be included in the MPUU.

Data issues

Data issues listed in this release note are limited to only those that affect the accuracy of the concept description. Issues are identified and tracked by the following method:

- The ID number is an internal identifier within the NEHTA issue management system.
- TGA Label Names are generally used wherever issues include product names.
- The TGA registration number (the ARTG or Licence ID number). In cases where the product is not registered by the TGA, a NEHTA identifier has been included.

ID	Known issues
AMT-2808	The unit dose form type of “ampoule” will be amended to “unit dose” in a future release, for ARTG 55364 OCUFEN flurbiprofen sodium 300 microgram/mL eye drops ampoule.
AMT-2809	The current ingredient “Sorbitol solution (70 per cent) (non-crystallising)” will be amended to “sorbitol” with a strength of 70% in a future release for ARTG 11287 Pfizer (Perth) SORBILAX.
AMT-249	The dose form for the medicinal concepts for the following product will be amended to “tablet: chewable” in a future release; <ul style="list-style-type: none">• ARTG 14369 Mylanta Double Strength tablet: chewable, 100, blister pack
AMT-280	Redundant information such as “1 tablet”, “tablets”, “diagnostic strips” and other redundant terms should have been removed during the transform of the data from v2. This has not always been applied across all terms so some terms still include this redundant information and appear the same as the term was in v2. This redundant information will be removed in future releases of v3.
AMT-275	
AMT-296	The ingredient order and Trade Product (TP) will be amended to align with the innovator products ⁹ for the following in a future release; <ul style="list-style-type: none">• ARTG 125607 Duotrav eye drops: solution, 2.5 mL, bottle• ARTG 23235 Prednefrin Forte eye drops: suspension, 10 mL, bottle
AMT-338	The dosage form for the following products will be amended to “tablet: sublingual” in a future release; <ul style="list-style-type: none">• ARTG 76662 Subutex 2 mg tablet, 7, blister pack• ARTG 76662 Subutex 2 mg tablet, 28, blister pack• ARTG 76662 Subutex 2 mg tablet, 100, bottle• ARTG 76663 Subutex 8 mg tablet, 7, blister pack• ARTG 76663 Subutex 8 mg tablet, 28, blister pack• ARTG 76663 Subutex 8 mg tablet, 100, bottle
AMT-354	Due to an issue identified in the v2 to v3 transform where the Preferred Term Other Identifying Information appears as a truncated description, the following product will be amended in a future release; <ul style="list-style-type: none">• ARTG 126721 Benadryl for the Family Day and Night, 1 pack, bottle
AMT-357	Due to an issue identified in the v2 to v3 transform where the Unit of Use Quantity appears as “1 each” the Medicinal Product Pack (MPP), Trade Product Pack (TPP) and Containered Trade Product Pack (CTPP) descriptions for the following product will be amended in a future release; <ul style="list-style-type: none">• ARTG 10005840 Glucaid 75 g/300 mL oral liquid: solution, 300 mL, bottle
AMT-362	Due to a decision made previously by the Support Group, all products with the dosage form of “injection: intravenous” will be inactivated in a future release of AMT and replaced with products with a dosage form of “injection: solution”.
AMT-367	All the products with ingredient “clotrimazole” and dosage form of “cream” will be reviewed, and those products which should have a dosage form of “vaginal cream” will be inactivated and replaced with products with the correct dosage form. The remaining products which have ingredient “clotrimazole” and the dosage form of “cream” will remain and not be inactivated.
AMT-368	The following products that currently have their Basis of Strength Substance (BoSS) strength expressed as salts will be inactivated in the future and replaced with new products with amended BoSSes based on the base of the salts; <ul style="list-style-type: none">• ARTG 10754 Hepasol oral liquid: solution, 200 mL, bottle• ARTG 10754 Hepasol oral liquid: solution, 500 mL, bottle

⁹ See “Medicinal Product Preferred Term brief definition” in the *AMT v3 Model Editorial Rules*. Refer to note 4 for the URL.

ID	Known issues
LIN-674	In AMT v2 the manufacturer's code for suppliers, such as Baxter, is placed at the end of the Containered Trade Product Pack (CTPP) Preferred Term descriptions. This code currently does not get added to the CTPP descriptions in v3 and it is anticipated the code will be added to the AMT v3 descriptions in a future release.
AMT-397	Due to an issue identified in the v2 to v3 transform where the Unit of Use Quantity appears as "2 aerosol cans" rather than "2 x 14 applications" the Medicinal Product Pack (MPP), Trade Product Pack (TPP) and Containered Trade Product Pack (CTPP) descriptions for the following product will be amended in a future release; <ul style="list-style-type: none"><li data-bbox="247 515 893 548">• ARTG 179575 Budenofalk 2 mg/application enema
AMT-417	The trade descriptions for all the extemporaneous products will be amended in a future release to include the monograph standard.
AMT-619	Due to an issue identified in the v2 to v3 transform where the Unit of Use Quantity appears as "1 each" the Medicinal Product Pack (MPP), Trade Product Pack (TPP) and Containered Trade Product Pack (CTPP) descriptions for the following products will be amended in a future release; <ul style="list-style-type: none"><li data-bbox="247 761 989 795">• ARTG 20011 MD-Gastroview solution, 12 x 120 mL bottles<li data-bbox="247 795 989 828">• ARTG 20011 MD-Gastroview solution, 12 x 240 mL bottles
AMT-834	Due to an issue identified in the v2 to v3 transform where the actual strength appears as a /mL strength rather than a /5mL strength the descriptions for the following product will be amended in a future release; <ul style="list-style-type: none"><li data-bbox="247 963 1061 996">• ARTG 78627 Kaletra 400/100 oral liquid: solution, 60 mL, bottle
AMT-846	The Trade Product (TP) will be amended from Actrapid HM to Actrapid for the following product in a future release; <ul style="list-style-type: none"><li data-bbox="247 1086 1300 1120">• ARTG 169625 Actrapid 100 international units/mL injection: solution, 1 x 10 mL vial
AMT-903	The strength representation will be amended from 10% (1 g/10 mL) to 953 mg/10 mL for the following product in a future release; <ul style="list-style-type: none"><li data-bbox="247 1220 1380 1276">• ARTG 22923 Calcium Gluconate (Phebra) 10% (1 g/10 mL) injection: solution, 10 x 10 mL vials The strength representation will be amended from 10% (5 g/50 mL) to 4.765g/50mL for the following product in a future release; <ul style="list-style-type: none"><li data-bbox="247 1355 1396 1411">• ARTG 167944 Calcium Gluconate (Phebra) 10% (5 g/50 mL) injection: solution, 10 x 50 mL vials
AMT-2313	Due to an issue identified in the v2 to v3 transform where the Unit of Use Quantity appears as "24 x 100mL packs" rather than "24 x 2 bag packs" the Medicinal Product Pack (MPP), Trade Product Pack (TPP), and Containered Trade Product Pack (CTPP) descriptions for the following products will be amended in a future release; <ul style="list-style-type: none"><li data-bbox="247 1579 1332 1646">• ARTG 48515 Sodium Chloride (Baxter) 0.9% (900 mg/100 mL) injection: intravenous infusion, 24 x 100 mL packs, bag<li data-bbox="247 1646 1332 1713">• ARTG 48515 Sodium Chloride (Baxter) 0.9% (900 mg/100 mL) injection: intravenous infusion, 100 mL pack, bag<li data-bbox="247 1713 1428 1780">• ARTG 48525 Glucose (Baxter) 5% (5 g/100 mL) injection: intravenous infusion, 24 x 100 mL packs, bag<li data-bbox="247 1780 1428 1848">• ARTG 48525 Glucose (Baxter) 5% (5 g/100 mL) injection: intravenous infusion, 100 mL pack, bag Due to an issue identified in the v2 to v3 transform where the AHB number has been removed, the CTPP descriptions for the following products will be amended in a future release; <ul style="list-style-type: none"><li data-bbox="247 1937 1332 2004">• ARTG 48515 Sodium Chloride (Baxter) 0.9% (900 mg/100 mL) injection: intravenous infusion, 24 x 100 mL packs, bag<li data-bbox="247 2004 1332 2072">• ARTG 48515 Sodium Chloride (Baxter) 0.9% (900 mg/100 mL) injection: intravenous infusion, 100 mL pack, bag

ID	Known issues
	<ul style="list-style-type: none">• ARTG 48515 Sodium Chloride (Baxter) 0.9% (900 mg/100 mL) injection: intravenous infusion, 100 mL bag• ARTG 48515 Sodium Chloride (Baxter) 0.9% (900 mg/100 mL) injection: intravenous infusion, 48 x 100 mL bags• ARTG 48525 Glucose (Baxter) 5% (5 g/100 mL) injection: intravenous infusion, 24 x 100 mL packs, bag• ARTG 48525 Glucose (Baxter) 5% (5 g/100 mL) injection: intravenous infusion, 100 mL pack, bag• ARTG 48525 Glucose (Baxter) 5% (5 g/100 mL) injection: intravenous infusion, 100 mL bag• ARTG 48525 Glucose (Baxter) 5% (5 g/100 mL) injection: intravenous infusion, 48 x 100 mL bags
AMT-2316	<p>Due to an issue identified in the v2 to v3 transform where the Unit of Use Quantity appears as "1 bead" rather than "30 bead" the Medicinal Product Pack (MPP), Trade Product Pack (TPP), and Containered Trade Product Pack (CTPP) descriptions for the following product will be amended in a future release;</p> <ul style="list-style-type: none">• ARTG 25538 Septopal Chain 7.5 mg implant, 1 bead, sachet• ARTG 159233 Septopal Chain 7.5 mg implant, 1 bead, sachet
AMT-2531	<p>The following AMT substance has not been mapped to an equivalent SNOMED CT substance. This will be amended in a future release;</p> <ul style="list-style-type: none">• SCTID 652791000168100 acridinium
AMT-3166	<p>The following AMT substance has not been mapped to an equivalent SNOMED CT substance. This will be amended in a future release;</p> <ul style="list-style-type: none">• SCTID 668851000168106 eribulin
AMT-3167	<p>The following AMT substance has not been mapped to an equivalent SNOMED CT substance. This will be amended in a future release;</p> <ul style="list-style-type: none">• SCTID 672641000168101 pomalidomide
AMT-3213	<p>The following AMT substance has not been mapped to an equivalent SNOMED CT substance. This will be amended in a future release;</p> <ul style="list-style-type: none">• SCTID 673271000168100 umeclidinium
AMT-3971	<p>The following AMT substance has not been mapped to an equivalent SNOMED CT substance. This will be amended in a future release;</p> <ul style="list-style-type: none">• SCTID 682171000168108 empagliflozin
AMT-3996	<p>The following AMT substance has not been mapped to an equivalent SNOMED CT substance. This will be amended in a future release;</p> <ul style="list-style-type: none">• SCTID 678211000168100 brentuximab vedotin

Implementation guidance

All AMT concepts have a Fully Specified Name (FSN), which is intended to provide an unambiguous name for the concept, and a Preferred Term (PT), which is intended to capture the common word or phrase used by Australian clinicians. System developers and end users should only implement Preferred Terms for clinical use, as these are the concepts developed for use by clinicians in Australia.

The NCTIS provides documentation specific to the Australian Medicines Terminology Release and SNOMED CT-AU, which can be downloaded from the [NEHTA eHealth Foundations](http://www.nehta.gov.au/implementation-resources/ehealth-foundations) page.¹⁰

¹⁰ <http://www.nehta.gov.au/implementation-resources/ehealth-foundations>.

Users may also benefit from referring to documentation provided with the SNOMED CT International terminology releases.

Safety guidance

NEHTA have applied their Clinical Safety Management System against the AMT development cycle and against reported incidents. This is to minimise the potential for clinical safety hazards to be introduced during the development of the AMT.

It is an expectation of implementers that they undertake their own risk assessment and management in the context of their own implementations of the AMT. In addition, it is expected that implementers will contact the AMT product support team with any questions or concerns about this in the first instance.

The AMT may be applied within a variety of use cases. NEHTA recommends that all licence holders planning on either developing a map or undertaking an implementation contact the NCTIS to discuss their intended uses.¹¹ This notification will allow Product Support Services to be made available as appropriate.

If licence holders become aware of any errors or omissions during their development they are advised to notify NEHTA as per clause 2.5 of the *Australian National Terminology Licence Agreement*, which states:

"If the Licensee becomes aware of any material error or change or correction needed in either the National Release or the International Release, the Licensee agrees to advise NEHTA promptly of such error, change or correction by following NEHTA's procedures for change notification that NEHTA prescribes and notifies to the Licensee from time to time."

To report an error, please email help@nehta.gov.au.

Product support services

The NCTIS has a dedicated Product Support team to help licence holders in their understanding and implementation of the AMT.

Support services can be tailored to customer requirements and range from general training and education on the terminology through to specific technical support. The following support channels are freely available:

- Email and phone support
- Downloadable resources from the [NEHTA eHealth Foundations](#) page (see note 10).
- Webinars
- Technical workshops
- Individual technical support at your workplace.

To request support or provide any other feedback, please email help@nehta.gov.au or phone 1300 901 001.

Future releases

The AMT is currently updated and made available to licence holders at the end of each month for download from the [NEHTA eHealth Foundations](#) page (see note 10).

¹¹ The NCTIS can be contacted via help@nehta.gov.au.

Previous releases

Date	Version
30 November 2014	EP-1859: 2014 Australian Medicines Terminology v3 Model v20141130 Release rationale: This release of the AMT includes products that become available on the Schedule of Pharmaceutical Benefits including the Repatriation Pharmaceutical Benefits Schedule (RPBS) on or before 1 December 2014.
31 October 2014	EP-1820: 2014 Australian Medicines Terminology v3 Model v20141031 Release rationale: This release of the AMT includes products that become available on the Schedule of Pharmaceutical Benefits including the Repatriation Pharmaceutical Benefits Schedule (RPBS) on or before 1 November 2014.
30 September 2014	EP-1794: 2014 Australian Medicines Terminology v3 Model v20140930 Release rationale: This release of the AMT includes products that become available on the Schedule of Pharmaceutical Benefits including the Repatriation Pharmaceutical Benefits Schedule (RPBS) on or before 1 October 2014.
31 August 2014	EP-1741: 2014 Australian Medicines Terminology v3 Model v20140831 Release rationale: This release of the AMT includes products that become available on the Schedule of Pharmaceutical Benefits including the Repatriation Pharmaceutical Benefits Schedule (RPBS) on or before 1 September 2014.
31 July 2014	EP-1720: 2014 Australian Medicines Terminology v3 Model v201407301 Release rationale: This release of the AMT includes products that become available on the Schedule of Pharmaceutical Benefits including the Repatriation Pharmaceutical Benefits Schedule (RPBS) on or before 1 August 2014.
30 June 2014	EP-1718: 2014 Australian Medicines Terminology v3 Model v20140630 Release rationale: The Australian Medicines Terminology v3 Model v20140630 is the first production release of the AMT in the v3 model structure and SNOMED CT Release Format 2 specification (RF2). This release follows the previously released Beta and Pre-Production versions. After the Beta release, feedback activities were conducted with external stakeholders, including vendors and jurisdictions, as well as government and research organisations. These activities helped to gauge the suitability of the AMT v3 Beta product by focusing on the AMT v3 model components, release files, and gaps in features and documentation. A number of recommendations for changes to the v3 model were identified during this period; details of these changes can be found in <i>Australian Medicines Terminology v3 – Beta Feedback Summary Results</i> . The data files for this release have been created using the May 2014 release (that is, AMT v2.56) as baseline data for the transformation to v3 model. No additional products have been included. This release of the AMT includes products that became available on the Schedule of Pharmaceutical Benefits including the Repatriation Pharmaceutical Benefits Schedule (RPBS) on or before 1 June 2014.

Document date: 31 December 2014

Contact for enquiries

Telephone: 1300 901 001 or email: help@nehta.gov.au

Disclaimer

The National E-Health Transition Authority Ltd (NEHTA) makes the information and other material ('Information') in this document available in good faith but without any representation or warranty as to its accuracy or completeness. NEHTA cannot accept any responsibility for the consequences of any use of the Information. As the Information is of a general nature only, it is up to any person using or relying on the Information to ensure that it is accurate, complete and suitable for the circumstances of its use.

Copyright © 2014 National E-Health Transition Authority Ltd

This document contains information which is protected by copyright. All Rights Reserved. No part of this work may be reproduced or used in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems—without the permission of NEHTA. All copies of this document must include the copyright and other information contained on this page.

Acknowledgement

The National E-Health Transition Authority is jointly funded by the Australian Government and all State and Territory Governments.